...
首页> 外文期刊>Cytogenetic and genome research >Sequence-specific modification of mouse genomic DNA mediated by gene targeting techniques
【24h】

Sequence-specific modification of mouse genomic DNA mediated by gene targeting techniques

机译:基因靶向技术介导的小鼠基因组DNA的序列特异性修饰

获取原文
获取原文并翻译 | 示例
           

摘要

The major impact of the human genome sequence is the understanding of disease etiology with deduced therapy. The completion of this project has shifted the interest from the sequencing and identification of genes to the exploration of gene function, signalling the beginning of the post-genomic era. Contrasting with the spectacular progress in the identification of many morbid genes, today therapeutic progress is still lagging behind. The goal of all gene therapy protocols is to repair the precise genetic defect without additional modification of the genome. The main strategy has traditionally been focused on the introduction of an expression system designed to express a specific protein, defective in the transfected cell. But the numerous deficiencies associated with gene augmentation have resulted in the development of alternative approaches to treat inherited and acquired genetic disorders. Among these one is represented by gene repair based on homologous recombination (HR). Simply stated, the process involves targeting the mutation in situ for gene correction and for restoration of a normal gene function. Homologous recombination is an efficient means for genomic manipulation of prokaryotes, yeast and some lower eukaryotes. By contrast, in higher eukaryotes it is less efficient than in the prokaryotic system, with non-homologous recombination being 10-50 fold higher. However, recent advances in gene targeting and novel strategies have led to the suggestion that gene correction based on HR might be used as clinical therapy for genetic disease. This site-specific gene repair approach could represent an alternative gene therapy strategy in respect to those involving the use of retroviral or lentiviral vectors to introduce therapeutic genes and linked regulatory sequences into random sites within the target cell genome. In fact, gene therapy approaches involving addition of a gene by viral or nonviral vectors often give a short duration of gene expression and are difficult to target to specific populations of cells. The purpose of this paper is to review oligonucleotide-based gene targeting technologies and their applications on modifying the mouse genome.
机译:人类基因组序列的主要影响是通过推论疗法了解疾病病因。该项目的完成将人们的兴趣从基因的测序和鉴定转移到了基因功能的探索上,标志着后基因组时代的开始。与鉴定许多病态基因的惊人进展相反,今天的治疗进展仍然落后。所有基因治疗方案的目标是在不对基因组进行额外修改的情况下修复精确的遗传缺陷。传统上,主要策略集中在引入表达系统的设计上,该表达系统旨在表达在转染细胞中有缺陷的特定蛋白质。但是,与基因扩增有关的众多缺陷导致了治疗遗传性和后天性遗传疾病的替代方法的发展。其中之一是基于同源重组(HR)的基因修复。简而言之,该过程涉及原位靶向突变以进行基因校正和恢复正常基因功能。同源重组是原核生物,酵母和一些低等真核生物的基因组操纵的有效手段。相比之下,在高等真核生物中,它的效率不如在原核生物系统中,非同源重组的效率高10-50倍。然而,基因靶向和新策略的最新进展导致提出这样的建议,即基于HR的基因校正可被用作遗传疾病的临床治疗方法。对于那些涉及使用逆转录病毒或慢病毒载体将治疗性基因和连接的调控序列引入靶细胞基因组内随机位点的方法,这种位点特异性基因修复方法可以代表一种替代的基因治疗策略。实际上,涉及通过病毒或非病毒载体添加基因的基因治疗方法通常会产生较短的基因表达时间,并且难以靶向特定的细胞群。本文的目的是综述基于寡核苷酸的基因靶向技术及其在修饰小鼠基因组中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号